Atlas Trials

A Randomized, Double-blind, Placebo-controlled Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JX2105 in Healthy Chinese Subjects

Clinical trial NCT06537050 · UNKNOWN

Trial details

NCT number
NCT06537050
Sponsor
Zhejiang Jingxin Pharmaceutical Co., Ltd.
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Parkinson's Disease
Start date
2024-07-01
Primary completion
2025-01-30
Enrollment
52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.